Management

Company

Board
Management

Scientific Advisors

IP Rights

Pharma Holdings Management

Pharma Holdings is a small and cost-effective company without its own laboratories or research facilities, using a network of high-quality contract research organizations and contract manufacturing organizations. The company has experienced advisors in all critical functions such as product development, regulatory affairs, design and execution of clinical trials. Agir AS is retained for administration and project management.

Christian Lütken, CEO

Christian Lütken holds an MD from the University of Oslo and has several
years of experience in the fields of pediatrics, family medicine, emergency medicine and occupational medicine. He has management experience as previous Head of Department in a private healthcare company. In recent years Christian has been working in DNB’s Global Healthcare team financing healthcare companies globally, and also working closely with the Norwegian healthcare startup scene comprising all subsegments of the healthcare industry including med.tech, pharma, bio tech, digital health and healthcare services.

christian.lutken(at)pharmaholdings.no
Christian is located in Oslo, Norway

Torsteinn Erlingsson, CFO

Mr. Erlingsson has been with Pharma Holdings AS since 2018. He holds a
Master Science degree in Fishery Science from UiT, the Arctic University of Norway. He has more than 25 years of experience from corporate finance and business development. In his tenure in corporate finance Erlingsson worked on several biotech transactions, and in Pharma Holdings Mr. Erlingsson has secured equity financing for the relaunch of the development of our lead drug candidate.

torsteinn.erlingsson(at)pharmaholdings.no
Torsteinn is located in Tromsø, Norway

Edvard Christian Fuglset Dahl

Edvard Christian Fuglset Dahl, CBDO

Mr Dahl has a bachelor in food&dairy technology, and have more than 25 years’ experience from health care industry, including pharma, medical devices and diagnostics, in different roles comprising sales, marketing and business development. His track record includes inter alia establishing a pharmaceutical company in Norway, and having scaled a digital diagnostic company internationally. Further, he has documented results in establishing distributor networks, distributor contracts, both exclusive and non-exclusive and has track record from merger & acquisitions – from screening fase, negotiations and final take over. His last position in Inven2 included working with health care startups, accelerating their commercial potential and contributing in key processes such as finding potential licensing partners.

edvard.dahl(at)pharmaholdings.no
Edvard is located in Oslo, Norway

Niklas Hammarstedt

Niklas Hammarstedt, CQO

Mr. Hammarstedt has a M.Sc. in chemistry, chemical and pharmaceutical engineering from KTH, the royal institute of technology in Stockholm Sweden.
He has more than 10 years of experience from working within the pharmaceutical and biotechnological industries specifically in roles within Quality Control, production management, project management and Quality Assurance.
The majority of his experience was gathered working at Octapharma AB starting in QC, then as Head of Production Documentation managing master batch records, batch record review and company SOPs, and finally working in QA. In his last position, as CQO at Atlas Antibodies AB, Niklas has been focusing on defining and building quality routines into a company-wide quality management system, from a compliance and sustainability perspective, combined with adapting best practices. Process compliance and efficiency together with supportive system implementation, integration and optimization were key needs and focus areas throughout previous positions.

niklas.hammarstedt(at)pharmaholdings.no
Niklas is located in Stockholm, Sweden

Johnny Ryvoll, VP Projects

Mr. Ryvoll has been with Pharma Holdings since 2018. He holds a MBA from University of Washington, Foster School of Business, and also a degree in Electrical Engineering (Siv. Ing.). He has more than 25 years of experience from corporate finance, project management and business development. In his tenure in corporate finance Mr. Ryvoll worked on several biotech transactions. In his time in Pharma Holdings he has built a network of high-quality contract research organizations and contract manufacturing capacity as well as networks of experienced advisors in all critical functions for the company such as product development, regulatory affairs, design and execution of clinical trials.

johnny.ryvoll(at)pharmaholdings.no
Johnny is located in Tromsø, Norway

Francois-Xavier Frapaise, CMO

FX Frapaise (Xavier) holds a MD from the University of Paris and brings on board over 40 years’ experience in the Pharma Industry (Sanofi, Abbott, Bayer, Merck, Gruenenthal as well as in several start-ups) in different roles such as VP R&D and Medical Affairs, CMO, CSO, and CEO. He has an extensive experience of international drug development (phase I to IV) and interaction with the FDA/EMA. One major focus of his experience is in the field of infectious diseases, such as Covid-19, RSV, hepatitis and C. difficile infections.

Xavier is located in Paris, France